Aptamer Group PLC

APTA

Equity

ISIN GB00BNRRP542 / Valor 115383974

LSE London Stock Exchange, SETS (2026-04-24)

GBP 0.006%

Aptamer Group PLC
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Aptamer Group PLC specializes in the discovery and development of Optimer binders, which are advanced aptamers designed to offer high affinity, specificity, and stability. These binders are cost-effective and are utilized in various applications across the life sciences sector, including therapeutic, diagnostic, and target-binding solutions. The company leverages its extensive experience and employs cutting-edge, high-throughput automated technologies to provide customized aptamer-based solutions to a global clientele. Aptamer Group's innovative approach aims to facilitate advancements in the life sciences by enhancing the performance and efficiency of molecular binding processes.

Summarized from source with an LLMView SourceSector: Technology

Revenue and gross margin

For the six months to 31 December 2024, Aptamer Group PLC reported revenue of £653k (H1 2024: £298k) and gross profit of £367k, driving a gross margin of 56% (H1 2024: 9%).

Profitability

Aptamer Group PLC reported an adjusted EBITDA loss of £1.073m (H1 2024: £1.759m) and a PAT loss of £1.112m (H1 2024: £1.807m), with administrative expenses reduced to £1.519m from £1.735m a year earlier.

Cash flow and fundraising

Net cash used in operations was £1.288m (improved from £1.757m in H1 2024). The group raised £2.623m net in August 2024 (issue of 1.45bn shares at 0.2p). Closing cash at 31 December 2024 was £1.967m (opening £0.87m); the report notes a post‑period R&D tax credit of £0.2m left cash at c.£2.0m at end‑February 2025.

Balance sheet highlights

As at 31 December 2024, Aptamer Group PLC had net assets of £2.562m (June 2024: £0.887m). Key balances include cash £1.967m, trade & other receivables £924k (higher due to increased commercial work), inventories £107k, and interest‑bearing loans & borrowings of £643k. Deferred income was £275k.

Operational progress and pipeline

Aptamer Group PLC secured multiple fee‑for‑service contracts (including extensions with Top‑20 pharma) and reports a sales pipeline of £5.1m (with £3.2m in advanced negotiations) and an order book of £0.5m in addition to the £0.7m recognised in H1. Notable collaborations include projects with Unilever, AstraZeneca and others, plus progress on delivery vehicles, diagnostics and assay kit opportunities.

Board, cost base and strategy

During the period Aptamer Group PLC restructured its board (new Non‑Executive Chair Dr Adam Hargreaves, CEO Dr Arron Tolley re‑appointed, and CFO Andrew Rapson added; Tim Sykes joined as NED) and reduced headcount to 28. The strategic focus is on advancing high‑value Optimer® assets towards licensing and downstream royalty opportunities.

Summarized from source with an LLMView Source

Key figures

118%1Y

-97.9%3Y

%5Y

Performance

89.3%1Y

149%3Y

131%5Y

Volatility